<DOC>
	<DOCNO>NCT00610857</DOCNO>
	<brief_summary>To determine safety efficacy combination HDI anti-CTLA-4 monoclonal antibody patient recurrent inoperable stage III stage IV melanoma .</brief_summary>
	<brief_title>Safety Efficacy Combination HDI Anti-CTLA4 Recurrent Inoperable Stage III Stage IV Melanoma</brief_title>
	<detailed_description>Immunity melanoma appear central disease control adjuvant advance disease setting . Spontaneous regression report melanoma , suggest role host immunity , indirectly support presence lymphoid infiltrate primary melanoma associate tumor regression .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients must write informed consent obtain prior initiation study procedure . Male female subject great equal 18 year age . Patients must histologically confirm recurrent stage III stage IV melanoma ( AJCC 6th edition classification ) . Cutaneous melanoma , ocular mucosal melanoma eligible . Patients must measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) . Baseline measurement must obtain within 4 week prior initiate therapy . Patients must adequate hematologic , renal , liver function evidence follow ( within 4 week prior start study drug ) : WBC great equal 3,000/mm3 Lymphocytes great equal 1,000/mm3 Platelets great equal 100,000/mm3 Serum Creatinine less equal 1.5 x upper limit normal ( ULN ) Serum Bilirubin less equal 1.5 x ULN Serum AST/ALT less equal 2.5 x ULN Serum LDH less equal 2.0 x ULN APTT less &lt; 40 Patients must fully recover effect major surgery , free significant detectable infection . Patients must receive chemotherapy , hormonal therapy , radiotherapy , biological therapy within precede 4 week . Patients must previous therapy AntiCTLA4 monoclonal antibody ( include CP675,206 MDX010 ) . Previous therapy Interferonalfa 2b adjuvant metastatic setting allow . Previous therapy biological agent ( include vaccine GMCSF ) allow . Patients must ECOG performance status 0 1 . Patients must autoimmune disorder ( except vitiligo ) . Patients positive titer autoimmune antibody allow study absence history clinical manifestation autoimmune disease . Patients must condition immunosuppression chronic requirement treatment systemic steroid , include oral steroid , continuous use topical steroid cream ointment , inhale steroid contain inhaler . Patients discontinue use class medication least 2 week eligible . Treatment steroid immunosuppressant medication allow study clinically require treat side effect relate autoimmunity may develop secondary study agent . Patients must free brain metastasis contrastenhanced CT/MRI scan within 4 week prior start study drug . If know prior brain metastasis , must evidence active brain disease two successive MRI evaluation least 3 month apart ( one £ 4 week prior start study drug ) . Female patient child bear potential must negative pregnancy test , must breast feeding . Patients must agree use effective contraception ( male female ) . Exclusion Criteria Serious illness , : cardiovascular disease ( uncontrolled congestive heart failure , hypertension , cardiac ischemia , myocardial infarction , severe cardiac arrhythmia ) , bleed disorder , autoimmune disease , severe obstructive restrictive pulmonary disease , active systemic infection , inflammatory bowel disorder . Treatment mitomycin C nitrosureas within six week prior study entry . Any significant psychiatric disease , medical intervention , condition , opinion principal investigator , could prevent adequate informed consent compromise participation clinical trial . Active infection antibiotic within oneweek prior study , include unexplained fever ( temp &gt; 38.1°C ) . Treatment anticoagulant , except keep indwell line patent . Systemic steroid immunosuppressive therapy within 4 week start study . Treatment investigational product within 28 day registration . History inflammatory bowel disease ( e.g . Crohn 's disease ulcerative colitis ) , celiac disease , chronic gastrointestinal condition associate diarrhea , current acute colitis origin , history diverticulitis ( even single episode ) evidence diverticulitis baseline , include evidence limit CTscan . Patients tolerate highdose interferonα therapy adjuvant set exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>